First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

BACKGROUND: CheckMate 9LA, a phase 3, randomized, open-label study in first-line advanced non-small cell lung cancer (NSCLC), showed significantly improved overall survival (OS) with nivolumab plus ipilimumab combined with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles). We present res...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Thomas, Sakai, Hiroshi, Ikeda, Satoshi, Cheng, Ying, Kasahara, Kazuo, Sato, Yuki, Nakahara, Yoshiro, Takeda, Masayuki, Kaneda, Hiroyasu, Zhang, Helong, Maemondo, Makoto, Minato, Koichi, Hisada, Takeshi, Misumi, Yuki, Satouchi, Miyako, Hotta, Katsuyuki, Li, Ang, Oukessou, Abderrahim, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956544/
https://www.ncbi.nlm.nih.gov/pubmed/35182247
http://dx.doi.org/10.1007/s10147-022-02120-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956544/
https://www.ncbi.nlm.nih.gov/pubmed/35182247
http://dx.doi.org/10.1007/s10147-022-02120-0

Ejemplares similares